Euclidean Capital overview
Stories about Euclidean Capital
Peltarion attracts $20 mln Series A
Peltarion, a Swedish operational AI company, has raised $20 million in Series A financing. Euclidean Capital led the round with participation from FAM and EQT Ventures.
Ripple Foods racks up $65 mln Series C
Ripple Foods, a maker of nutritious plant-based dairy alternatives, has secured $65 million in Series C funding. Euclidean Capital led the round with participation from other investors that included Goldman Sachs, Fall Line Capital, GV, Prelude Ventures, S2G Ventures and Khosla Ventures.
Euclidean Capital contact information
Offices
160 Fifth Avenue, 9th Floor, New York, 10010, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Ashvin Chhabra | Job titlePresident and Chief Investment Officer | LocationNew York, United States | Email  --------- |
| Mr. Sloane Damiano | Job titleController | LocationNew York, United States | Email ------- |
| Mr. Colin Mackintosh | Job titleInvestment Associate | LocationNew York, United States | Email ---------- |
| Ms. Monique Miller | Job titleHead of Investment Strategy | LocationNew York, United States | Email --------- |
Euclidean Capital fund commitments
Known fund commitments: 1
| Fund | Manager | Commitment date | Commitment size |
|---|---|---|---|
Manager ----- | Commitment dateDec 2024 | Commitment size- | |
Stories that mention Euclidean Capital
Leal Therapeutics inks $30m Series A
SV Health Investors' Dementia Discovery Fund led the round.
VC-backed Stablix appoints Saiah as CSO
Most recently, he was CSO at Navitor Pharmaceuticals.
VC-backed Stablix recruits Kingsley as CEO
Most recently, he was president and CEO of Scholar Rock.
April procures $10m seed
April, a tax platform, has raised $10 million in seed funding.
Duality Technologies lands $30m Series B
Duality Technologies, a provider of privacy-enhanced data collaboration solutions, has secured $30 million in Series B funding.
ASAPP picks up $120m Series C
ASAPP Inc, an artificial intelligence research-driven company, has raised $120 million in Series C financing.
A2 Biotherapeutics scores $71.5m Series B
Agoura Hills, California-based A2 Biotherapeutics, a developer of cell therapies for solid tumor cancer patients, has raised $71.5 million in Series B financing.
Nura Bio reels in $73m Series A
South San Francisco-based Nura Bio Inc, a biopharma company focused on developing neuroprotective drugs, has raised $73 million in Series A funding.